Thus, as measured by MTT assays (Figs 6B and S6B) and flow cytometry (Figs 6C and S6C), both PRMT6 and RBM39 maintained cancer cell growth and CSC-like properties under Indisulam treatment, unlike E155/164A or R92K. Here, PRMT6 is linked to cancer.